Rare immune-mediated neurological Side Effects under Anti-PD-1 Antibody Therapy

被引：0
|
作者：
Gellrich, F. F. [1 ]
Meier, F. [1 ]
机构：
[1] Univ Klinikum Carl Gustav Carus Dresden, Dermatol, Dresden, Germany
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2018年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
FV12
引用
下载
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [21] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
    Gide, Tuba N.
    Quek, Camelia
    Menzies, Alexander M.
    Tasker, Annie T.
    Shang, Ping
    Holst, Jeff
    Madore, Jason
    Lim, Su Yin
    Velickovic, Rebecca
    Wongchenko, Matthew
    Yan, Yibing
    Lo, Serigne
    Carlino, Matteo S.
    Guminski, Alexander
    Saw, Robyn P. M.
    Pang, Angel
    McGuire, Helen M.
    Palendira, Umaimainthan
    Thompson, John F.
    Rizos, Helen
    da Silva, Ines Pires
    Batten, Marcel
    Scolyer, Richard A.
    Long, Georgina V.
    Wilmott, James S.
    CANCER CELL, 2019, 35 (02) : 238 - +
  • [22] Paraneoplastic immune-mediated neurological effects of systemic cancers
    Sioka, Chrissa
    Fotopoulos, Andreas
    Kyritsis, Athanassios P.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2014, 10 (05) : 621 - 630
  • [23] Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takuya
    Hachiga, Kosuke
    Shichino, Shigeyuki
    Terashima, Yuya
    Toda, Etsuko
    Shand, Francis H. W.
    Kakimi, Kazuhiro
    Ito, Satoru
    Matsushima, Kouji
    CANCER IMMUNOLOGY RESEARCH, 2015, 3 (06) : 631 - 640
  • [24] Therapy of the metastatic Merkel Cell Carcinoma with the Anti-PD-1 Antibody Pembrolizumab
    Meier, K.
    Wilhelmi, J.
    Lomberg, D.
    Spaenkuch, I
    Scheu, A.
    Leiter, U.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2017, 15 : 171 - 171
  • [25] Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
    Su, Xin
    Li, Jian
    Xu, Xiao
    Ye, Youbao
    Wang, Cailiu
    Pang, Guanglong
    Liu, Wenxiu
    Liu, Ang
    Zhao, Changchun
    Hao, Xiangyong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [26] Robust anti-tumor effects of combined anti-CD4 depleting antibody and anti-PD-1/PD-L1 immune checkpoint antibody treatment in mice
    Ito, Satoru
    Matsushima, Kouji
    Ueha, Satoshi
    Yokochi, Shoji
    Ishiwata, Yoshiro
    Hachiga, Kosuke
    Ogiwara, Haru
    Chand, Krishant
    Nakajima, Takumi
    CANCER RESEARCH, 2015, 75
  • [27] Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma
    Kaehler, Katharina C.
    Hassel, Jessica C.
    Heinzerling, Lucie
    Loquai, Carmen
    Moessner, Rotraut
    Ugurel, Selma
    Zimmer, Lisa
    Gutzmer, Ralf
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 (07): : 662 - 681
  • [28] Immune Signatures for the Response and Occurrence of immune-mediated Side Effects under Immune Checkpoint Inhibitor Therapy in Stage IV Melanoma Patients
    Reschke, R.
    Gussek, P.
    Boldt, A.
    Sack, U.
    Koehl, U.
    Lordick, F.
    Kreuz, M.
    Reiche, K.
    Simon, J. C.
    Ziemer, M.
    Kunz, M.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 7 - 8
  • [29] Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy
    Novotny, J. F., Jr.
    Cogswell, J.
    Inzunza, H.
    Harbison, C.
    Horak, C.
    Averbuch, S.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1966 - 1969
  • [30] Immune-related adverse events with resumed anti-PD-1 therapy
    Reactions Weekly, 2017, 1676 (1) : 4 - 4
12345